Filing Analysis
OSR Health, Inc. has been notified that a Nasdaq Hearings Panel has scheduled a hearing for September 29, 2026, to appeal a delisting determination. While trading in the company's securities was suspended on August 26, 2026, the hearing request has stayed the formal filing of a Form 25-NSE.
🚩 Red Flags
- Trading suspension is already in effect (as of August 26, 2026).
- Uncertainty regarding the Panel's decision to grant continued listing.
- Risk of formal delisting via Form 25-NSE if the appeal is unsuccessful.
📋 Key Facts
- Nasdaq Hearings Panel hearing scheduled for September 29, 2026, at 10:00 a.m. ET.
- Trading in OSRH securities was suspended effective at the opening of business on August 26, 2026.
- The company has appealed the Staff's delisting determination.
- The timely hearing request has stayed the filing of Form 25-NSE (formal delisting).
- The company is preparing a plan to regain and sustain compliance with Nasdaq listing requirements.
OSR Health, Inc. has requested a hearing with a Nasdaq Hearings Panel to appeal a delisting determination resulting from non-compliance with the minimum bid price requirement. Trading is scheduled to be suspended on August 26, 2026, though the formal delisting (Form 25-NSE) is stayed pending the panel's decision.
🚩 Red Flags
- Imminent suspension of trading (scheduled for August 26, 2026).
- Failure to meet minimum bid price requirement (Rule 5550(a)(2)).
- Company has already used its second 180-day compliance period, leaving no room for standard extensions.
- High uncertainty regarding the Panel's decision to allow continued listing.
📋 Key Facts
- Nasdaq issued a Staff Determination Letter to delist common stock and warrants for non-compliance with Nasdaq Listing Rule 5550(a)(2) (minimum bid price).
- The Company has exhausted its previous 180-day compliance period.
- A request for a hearing before a Nasdaq Hearings Panel was submitted on August 25, 2026.
- Trading suspension is scheduled for the opening of business on August 26, 2026.
- The timely hearing request stays the filing of Form 25-NSE (formal delisting) pending the Panel's decision.
OSR Health, Inc. received a Staff Determination Letter from Nasdaq notifying the company of its intent to delist its common stock and warrants. The delisting is due to failure to meet the minimum $1.00 bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
🚩 Red Flags
- Delisting determination issued by Nasdaq.
- Failure to meet minimum bid price requirement ($1.00).
- Exhaustion of previous compliance periods (second 180-day period already used).
- Imminent suspension of trading (scheduled for August 26, 2026).
📋 Key Facts
- Nasdaq determined the company failed to regain compliance by the August 31, 2026, deadline.
- Trading in OSRH common stock and OSRHW warrants is scheduled to be suspended at the opening of business on August 26, 2026.
- The company intends to request a hearing before a Nasdaq Hearings Panel by 4:00 p.m. ET on August 26, 2026.
- A timely hearing request is expected to stay the filing of Form 25-NSE, preventing final formal delisting pending the Panel's decision.
- The company has already exhausted a second 180-day compliance period.
OSR Health, Inc. reported the results of its annual meeting of stockholders held on August 7, 2026. The company successfully re-elected seven directors and obtained shareholder approval for auditor ratification, executive compensation, and an increase in authorized shares.
📋 Key Facts
- Annual Meeting held on August 7, 2026.
- Quorum was established with 21,088,120 shares (approx. 60.05% of outstanding common stock) present.
- Seven directors were re-elected to serve until the 2027 Annual Meeting: Kuk Hyoun Hwang, Jun Chul Whang, Alcide Barberis, Seng Chin Mah, Hyuk Joo Jee, Joong Myung Cho, and Reto Fierz.
- Stockholders approved the Ratification of Independent Auditor Proposal (20,296,535 votes FOR).
- Stockholders approved the Executive Compensation Proposal (15,059,135 votes FOR).
- Stockholders approved an Authorized Shares Increase Proposal (19,922,498 votes FOR).
OSR Health, Inc. issued a clarification regarding its communication with Nasdaq concerning its 'Shareholder Loyalty Contingent Value Rights (CVR)' program. The company clarified that Nasdaq has not endorsed the CVR program and only provided technical feedback regarding potential mechanical stock price adjustments.
🚩 Red Flags
- Potential regulatory/exchange scrutiny: The need to clarify that Nasdaq has NOT endorsed the company's CVR program suggests previous investor confusion or misleading implications in prior communications.
- Complexity of CVR programs: These instruments can be highly complex and often lead to significant volatility or litigation if not clearly understood by shareholders.
📋 Key Facts
- Clarification issued on August 7, 2026, regarding a July 31, 2026 press release.
- Nasdaq's previous communication was limited to technical questions about ex-date price adjustments.
- Nasdaq has not expressed a definitive opinion or endorsement of the CVR program.
- The record date for the CVR program remains August 14, 2026.
OSR Health, Inc. announced that Nasdaq has verbally communicated that the company's Shareholder Loyalty Contingent Value Rights (CVR) program will not trigger a mechanical price adjustment to the common stock.
🚩 Red Flags
- Potential volatility associated with CVR distributions and subsequent share deliveries.
📋 Key Facts
- Nasdaq stated via verbal communication that CVR distribution/delivery will not result in a price adjustment for OSRH common stock.
- The communication relates specifically to exchange-mandated price adjustments, not an endorsement of the program itself.
- The company's regulatory process regarding the CVR distribution remains ongoing.
OSR Health, Inc. (formerly OSR Holdings, Inc.) announced a corporate name change and the filing of a Certificate of Revival of Charter with the State of Delaware effective June 11, 2026. The company remains listed on Nasdaq under the same tickers (OSRH and OSRHW).
🚩 Red Flags
- The use of a 'Certificate of Revival' suggests the company's charter may have previously lapsed or been voided, though the filing asserts they are now in good standing.
📋 Key Facts
- Corporate name changed from 'OSR Holdings, Inc.' to 'OSR Health, Inc.' effective June 11, 2026.
- The change was executed via a Certificate of Revival of Charter filed with the Secretary of State of Delaware.
- The filing renewed and revived the Company's certificate of incorporation, confirming the company is in good standing.
- Nasdaq ticker symbols OSRH (Common Stock) and OSRHW (Warrants) remain unchanged.
- No approval from stockholders was required for this change under DGCL Sections 312 and 242(b)(1).
OSR Holdings, Inc. has postponed its 2026 Annual Meeting of Stockholders, originally scheduled for June 18, 2026. The company stated that additional time is needed to evaluate matters relating to the meeting and the business to be presented, but has not yet set a new date.
🚩 Red Flags
- Vague justification for postponement ('evaluate certain matters') often precedes negative news, management disputes, or proxy fight complications
- Postponement occurred only 13 days prior to the scheduled meeting date
📋 Key Facts
- Original Annual Meeting date: June 18, 2026
- Postponement announced on: June 5, 2026
- Filing date: June 11, 2026
- No new date has been established for the meeting
- Company cited the need to evaluate 'certain matters relating to the Annual Meeting and the business to be presented'
OSR Holdings, Inc. entered into an Asset Purchase Agreement on May 27, 2026, to acquire the VXM01 intellectual property family from Vaximm AG for $30,000,000. Vaximm AG is an indirect subsidiary of the Company, making this a related-party transaction.
🚩 Red Flags
- Related-party transaction: The seller, Vaximm AG, is an indirect subsidiary of the buyer, OSR Holdings.
- Significant liability: The company has committed to a $30 million payment, which is substantial for a micro-cap entity.
- Contingent payment: The payment is tied to clinical milestones (Phase 2 study), introducing binary regulatory risk.
📋 Key Facts
- Purchase price for the VXM01 intellectual property family is $30,000,000.
- Payment is due in full upon the completion of a Phase 2 clinical study of VXM01 in either glioblastoma (GBM) or pancreatic ductal adenocarcinoma (PDAC).
- The transaction transfers ownership of IP from Vaximm (an indirect subsidiary) to OSR Holdings.
- The agreement may be terminated if closing has not occurred by December 31, 2027.
- The agreement is governed by the laws of Switzerland.
This is an 8-K/A amendment filed to provide a missing exhibit (a fairness opinion) related to a previously disclosed Global Exclusive License Agreement. The filing does not change the underlying terms of the agreement but completes the regulatory disclosure requirements.
📋 Key Facts
- The filing is an amendment (No. 1) to a report originally filed on April 30, 2026.
- The primary purpose is to include Exhibit 99.2, a Fairness Opinion from Avance Life Sciences AG dated April 21, 2026.
- The underlying transaction is a Global Exclusive License Agreement for VXM01 with BCM Europe and Vaximm AG, valued at $815 million (per Exhibit 99.1 reference).
- The agreement and associated Pledge Agreement were dated April 29, 2026.
OSR Holdings entered into a massive $815 million global exclusive license agreement for its VXM01 cancer immunotherapy platform with its largest shareholder, BCM Europe AG. The deal includes a $15 million equity put option and a pledge of nearly 10 million shares as collateral for milestone payments.
🚩 Red Flags
- The transaction is with the company's largest shareholder (related-party).
- The share pledge intended to secure $815M in milestones does not become effective until February 2028 due to lock-up restrictions.
- The $815M figure is heavily contingent on milestones and lacks a disclosed immediate upfront cash payment.
📋 Key Facts
- The agreement grants BCM Europe AG (BCME) exclusive worldwide rights to develop and commercialize VXM01, an oral DNA-based cancer immunotherapy.
- BCME is the company's largest shareholder, making this a related-party transaction.
- Total potential milestone payments aggregate to $815,000,000.
- OSR Holdings received an equity put option to sell up to $15,000,000 of common stock to BCME at $10.00 per share.
- BCME and affiliates pledged 9,974,728 shares of OSRH common stock as collateral, though the pledge is not effective until February 15, 2028.
- The company expects to pay $30,000,000 to its subsidiary Vaximm AG to acquire certain IP rights related to the deal.
OSR Holdings, Inc. has appointed Yeiseok Kim as its new Chief Operating Officer, effective April 16, 2026. Mr. Kim transitions to the role from a Senior Analyst position at the company's subsidiary, OSR Holdings Co., Ltd.
📋 Key Facts
- Yeiseok Kim appointed as Chief Operating Officer effective April 16, 2026
- Mr. Kim will receive an annual base salary of KRW 240,000,000 (approximately $174,000 USD)
- Appointee previously served as a Senior Analyst at OSR Holdings Co., Ltd. from 2020 to 2025
- Mr. Kim holds a Korean medical license (2019) and an MS in Medicine from Jeonbuk National University
- Compensation includes participation in the company's Equity-based Compensation Plan
OSR Holdings entered into a $1.05 million senior secured convertible note and amended its existing equity line of credit (ELOC) with White Lion Capital. The financing provides $500,000 in immediate cash and cancels $2.02 million in warrants, but is secured by substantially all company assets with a short 9-month maturity.
🚩 Red Flags
- Debt is secured by 'substantially all of the Company’s assets', putting the entire business at risk upon default.
- Extremely short maturity period of 9 months for the convertible note.
- Potential for 'death spiral' dilution due to discounted market-based conversion prices and ELOC purchases at 90% of VWAP.
- The company accepted a $1.05M debt obligation while only receiving $500k in actual cash.
📋 Key Facts
- Issued a Senior Secured Convertible Promissory Note for $1,055,555.55 to White Lion Capital.
- Received $500,000 in cash and cancelled $2,019,290 in existing warrants as consideration.
- The Note matures in 9 months (January 2027) and carries a 5% interest rate.
- The Note is convertible at $1.00 per share or a discounted market-based price under certain conditions.
- Amended ELOC allows for intraday and fixed purchase notices at 90% of VWAP (a 10% discount).
- The debt is secured by substantially all of the Company’s assets.
OSR Holdings, Inc. filed an 8-K/A amendment to correct clerical errors in a previously filed Global License Agreement for VXM01 dated March 23, 2026. The amendment specifically corrects the stated per share price within the agreement.
🚩 Red Flags
- Correction of pricing in a material agreement can sometimes indicate poor internal controls or lack of diligence in initial filings.
📋 Key Facts
- The filing is an Amendment No. 1 to a Current Report on Form 8-K originally filed on April 2, 2026.
- The primary purpose is to replace Exhibit 10.1 (Global License Agreement for VXM01) with a corrected version.
- The correction addresses clerical errors, specifically the 'stated per share price'.
- The agreement involves Vaximm AG, OSR Holdings, Inc., and BCM Europe AG.
OSR Holdings and its subsidiary Vaximm AG entered into a binding term sheet with BCM Europe AG for a revised global exclusive license for VXM01, featuring up to $815 million in milestone payments. The agreement replaces a previous 2025 term sheet and introduces OSR Holdings as a direct counterparty and primary recipient of payments.
🚩 Red Flags
- The agreement is still subject to the execution of a definitive agreement and receipt of an independent fairness opinion.
- The company is committing to a $30.0 million development financing facility for its subsidiary, which may strain capital resources.
- There are date inconsistencies in the filing text (referencing both 2025 and 2026 for the event date).
📋 Key Facts
- Binding Term Sheet signed on March 27, 2026, with BCM Europe AG (BCME).
- BCME granted an exclusive, worldwide, sublicensable license to develop and commercialize VXM01.
- Potential milestone payments to OSR Holdings total up to $815.0 million.
- OSR Holdings will provide Vaximm with a development financing facility of up to $30.0 million.
- The agreement is subject to a definitive license agreement, board approvals, and an independent fairness opinion.
OSR Holdings filed this 8-K to publicly disclose information inadvertently shared with a sell-side analyst regarding potential strategic transactions. The disclosures involve active licensing negotiations for a Phase 2 clinical asset and exploratory talks to acquire a controlling interest in a South Korean biopharmaceutical company.
🚩 Red Flags
- Inadvertent disclosure of material non-public information to a specific analyst prior to public release.
- Potential for significant capital expenditure or dilution if the acquisition of a 16% stake in a publicly-listed foreign company proceeds.
📋 Key Facts
- Inadvertent disclosure occurred on March 13, 2026, during an introductory investor relations call with a New York-based healthcare analyst.
- Subsidiary Vaximm AG is in active negotiations with SillaJen, Inc. (KOSDAQ: 215600) for a licensing arrangement involving Pexa-Vec, a Phase 2 oncolytic immunotherapy.
- OSR Holdings is in early-stage exploratory discussions to acquire a controlling interest (approximately 16%) in SillaJen.
- The company stated that no binding term sheets, letters of intent, or definitive agreements have been executed for either potential transaction.
- The filing was made specifically to satisfy Regulation FD requirements after the private disclosure.
OSR Holdings, Inc. received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement. The company now has until August 31, 2026, to meet the requirement or face potential delisting.
🚩 Red Flags
- The stock has failed to maintain a $1.00 share price for over six months.
- Potential for a reverse stock split if the share price does not recover organically by August 2026.
📋 Key Facts
- Received written notice from Nasdaq on March 5, 2026, granting an extension.
- The new deadline to regain compliance with Nasdaq Listing Rule 5550(a)(2) is August 31, 2026.
- The initial deficiency notice was received on September 5, 2025, after the stock traded below $1.00 for 30 consecutive business days.
- To regain compliance, the stock must maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
- The company qualified for the extension by meeting all other Nasdaq Capital Market initial listing requirements except for the bid price.
OSR Holdings, Inc. completed the acquisition of Woori IO Co., Ltd., a South Korean medical device company specializing in non-invasive biosensing technology for glucose monitoring. The transaction was executed via a share exchange through a subsidiary.
🚩 Red Flags
- Complexity of cross-border acquisition involving a South Korean entity and multiple subsidiary layers.
📋 Key Facts
- Closing Date: January 26, 2026.
- Target Company: Woori IO Co., Ltd. (WORIO), based in South Korea.
- Transaction Structure: Share exchange under the Korean Commercial Act; WORIO is now a wholly owned subsidiary of OSRK (a subsidiary of OSR Holdings).
- Exchange Ratio: Each WORIO share was exchanged for 0.948832 shares of OSRK.
- Issuance: OSRK issued 84,338 newly issued shares to former WORIO shareholders in exchange for 88,891 WORIO shares.
- No common stock of the parent company (OSRH) was issued in this transaction.
OSR Holdings, Inc. announced that its subsidiary, Vaximm AG, entered into a binding term sheet with BCM Europe AG, the company's largest shareholder, for an exclusive global license of the VXM01 immunotherapy platform. The deal includes a $30 million upfront payment and potential milestones totaling $815 million.
🚩 Red Flags
- Related-party transaction: The deal is with the company's largest shareholder (BCM Europe AG).
- Non-standard consideration: $15 million of the upfront payment is in 'digital assets', which carries significant valuation and liquidity risk.
- High dependency on milestone payments: A large portion of the reported value ($815M) is contingent upon future clinical/regulatory success.
📋 Key Facts
- Date of Term Sheet: January 13, 2025
- Counterparty: BCM Europe AG (identified as the Company's largest shareholder)
- Upfront Payment: $30.0 million ($15.0M cash and $15.0M in digital assets)
- Milestone Potential: Up to $815.0 million in clinical, regulatory, and commercial payments
- Subject Matter: Global exclusive, sublicensable license for VXM01 oral cancer immunotherapy platform
- Condition Precedent: Execution of a definitive agreement is subject to an independent third-party fairness opinion
OSR Holdings, Inc. announced that its subsidiary, Vaximm AG, entered into a non-binding global license term sheet with BCM Europe AG regarding the VXM01 oral immunotherapy platform. Notably, BCM Europe AG is identified as the Company's largest shareholder.
🚩 Red Flags
- Related-party transaction: The counterparty (BCM Europe AG) is the company's largest shareholder, creating significant potential for conflict of interest in negotiations.
- Non-binding nature: The agreement is currently only a term sheet and does not constitute a definitive agreement.
📋 Key Facts
- Vaximm AG (subsidiary) entered into a non-binding Global License Agreement Term Sheet with BCM Europe AG on November 21, 2025.
- The potential deal involves an upfront payment of $20 million and up to $815 million in milestones.
- BCM Europe AG is the largest shareholder of OSR Holdings, Inc.
- The term sheet includes an exclusivity period for negotiations.
OSR Holdings, Inc. (via its subsidiary OSRK) has entered into a definitive agreement to acquire Woori IO Co., Ltd., a South Korean medical-device company specializing in non-invasive glucose monitoring technology. The transaction is structured as a share exchange valued at approximately $10.6 million USD.
🚩 Red Flags
- The transaction involves an issuance of new equity (84,338 OSRK shares) which may result in dilution for existing shareholders.
- Complexity of the cross-border share exchange and contingent conversion ratio adds structural complexity to the capital structure.
📋 Key Facts
- Acquisition of Woori IO Co., Ltd. (WORIO) via a Share Exchange Agreement dated October 13, 2025.
- Transaction value: Approximately KRW 15 billion (~$10.6 million USD).
- Exchange ratio: Each WORIO share will be exchanged for 0.948832 OSRK shares; OSRK to issue 84,338 new shares.
- Target company (WORIO) provides technical development services to Samsung Electronics under a non-dilutive funding agreement.
- Closing is subject to shareholder approval (target date Dec 19, 2025) and regulatory clearances; expected effective date Jan 12, 2026.
- Contingent conversion: If OSRH stock reaches $10.00 on NASDAQ within three years post-closing, OSRK shares may be exchanged for OSRH common stock at a ratio of 12.96:1.
OSR Holdings, Inc. reported the results of its annual meeting of stockholders held on September 17, 2025. The meeting resulted in the election of seven directors and the approval of several key shareholder proposals including executive compensation and an equity plan.
🚩 Red Flags
- Two director nominees (Jin Whan Park and Phil Geon Lee) were not elected, indicating potential shareholder dissatisfaction or lack of support for specific board candidates.
📋 Key Facts
- Annual Meeting held on September 17, 2025.
- Quorum was established with 61.73% of outstanding shares (13,325,691 shares) present in person or by proxy.
- Seven out of nine director nominees were elected to serve until the 2026 Annual Meeting.
- Stockholders approved the Executive Compensation Proposal.
- Stockholders approved the Equity Plan Proposal.
- Stockholders approved the Nasdaq 20% Issuance Proposal.
OSR Holdings, Inc. received a notice from Nasdaq stating it is non-compliant with the minimum bid price requirement after its stock closed below $1.00 for 30 consecutive business days. The company has until March 4, 2026, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq
- Stock price has been below $1.00 for 30 consecutive business days
- Potential requirement for a reverse stock split to regain compliance
📋 Key Facts
- Received written notice from Nasdaq on September 5, 2025.
- Non-compliance is due to violation of Nasdaq Listing Rule 5550(a)(2) (minimum bid price requirement).
- The stock closed below $1.00 for 30 consecutive business days.
- Initial compliance period granted until March 4, 2026.
- Compliance can be achieved if the closing bid price is at least $1.00 for ten consecutive business days.
- Company may be eligible for an additional 180-day extension if certain market value and listing standards are met.
OSR Holdings, Inc. reports that Chardan Capital Markets, LLC has filed a lawsuit in the Southern District of New York against the Company and its CEO, Kuk Hyoun Hwang. The legal action seeks approximately $2.07 million and 34,500 shares of deferred equity related to previously disclosed SEC filings.
🚩 Red Flags
- Legal action targeting both the company and the CEO personally.
- Litigation involves potential disputes over accuracy of prior SEC disclosures (Form 10-Q).
- Financial liability of $2.07M plus equity could be material for a micro-cap entity.
📋 Key Facts
- Lawsuit filed on September 2, 2025, in the U.S. District Court for the Southern District of New York (Case No. 1:25-cv-07285).
- Plaintiff is Chardan Capital Markets, LLC.
- Defendants are OSR Holdings, Inc. and CEO Kuk Hyoun Hwang.
- Damages sought include ~$2,070,000 in cash and 34,500 shares of deferred equity, plus attorneys' fees.
- The litigation relates to matters disclosed in previous SEC filings, specifically the Form 10-Q filed on August 14, 2025.
OSR Holdings, Inc. entered into amendments to a Note Purchase Agreement and Common Stock Purchase Warrant with White Lion Capital, LLC. The amendment mandates that the company convene a stockholder meeting by September 19, 2025, to seek approval for various transactions and securities issuances, including those exceeding the Nasdaq 19.99% cap.
🚩 Red Flags
- High-pressure deadline: Company must act by September 19, 2025.
- Significant liquidity risk: Failure to comply results in an immediate $400,000 cash penalty.
- Potential dilution/Governance issues: Seeking shareholder approval for issuances exceeding the Nasdaq 19.99% cap suggests significant potential dilution of existing shareholders.
📋 Key Facts
- Amendment No. 1 to Note Purchase Agreement signed August 10, 2025.
- Company must convene a stockholder meeting prior to September 19, 2025.
- Stockholder approval is required for transactions under the Note Purchase Agreement and all other related instruments/warrants.
- Approval requested specifically for issuances exceeding the Nasdaq Rule 5635 Exchange Cap (19.99%).
- Failure to convene the meeting constitutes a material breach, triggering $400,000 in immediate cash liquidated damages payable to White Lion Capital.
OSR Holdings, Inc. announced an investor presentation to be held on August 6, 2025, in connection with an Investor Event.
📋 Key Facts
- The company is hosting an investor presentation on August 6, 2025.
- Presentation materials are attached as Exhibit 99.1 and will be available on the IR website.
- The filing includes disclosure under Item 7.01 (Regulation FD Disclosure).
OSR Holdings, Inc. entered into a non-binding term sheet to acquire Woori IO Co., Ltd. via a share exchange transaction. Under the proposed deal, WORIO would become a wholly owned subsidiary of OSRK (the Company's parent/affiliate), with shareholders receiving shares that may be convertible into OSRH common stock.
🚩 Red Flags
- Transaction is currently 'non-binding' and subject to further negotiation, meaning deal certainty is low.
- Potential dilution for existing shareholders through the issuance of new shares and potential conversion of those shares into common stock.
📋 Key Facts
- Entered into a non-binding term sheet on July 24, 2025, with Woori IO Co., Ltd. (WORIO).
- The transaction is structured as a share exchange where WORIO becomes a wholly owned subsidiary of OSRK.
- WORIO shareholders would receive newly issued shares of OSRK, potentially convertible into Company common stock within three years.
- The agreement includes a six-month exclusivity period and mutual due diligence requirements.
- The transaction is subject to the negotiation and execution of definitive agreements.
Sang Hyun Kim has resigned from the Board of Directors and his role as an independent director, effective June 26, 2025. The company stated the resignation was not due to any disagreement regarding operations, policies, or practices.
📋 Key Facts
- Resignation date: June 26, 2025
- Departing individual: Sang Hyun Kim
- Role: Member of the Board of Directors and Independent Director
- Stated reason: No dispute or disagreement with the Company's operations, policies, or practices.
OSR Holdings, Inc. entered into a multi-layered financing agreement with White Lion Capital, LLC involving $1.11 million in convertible notes and an amendment to an Equity Line of Credit (ELOC) for up to $78.9 million. The deal includes significant dilution risks through warrants and discounted conversion features.
🚩 Red Flags
- Heavy dilution risk via an massive $78.9 million Equity Line of Credit (ELOC).
- Highly dilutive conversion terms: Notes convert at a 5% discount to the lowest VWAP.
- Warrant issuance allows for significant equity accumulation by the investor ($4M worth).
- The structure is typical of 'death spiral' financing where the share price drop triggers more dilution.
📋 Key Facts
- Entered into a Note Purchase Agreement with White Lion Capital, LLC on May 6, 2025.
- Two Convertible Notes totaling $1,110,000 at 5% interest; first $400,000 note closes upon S-1 filing, second upon effectiveness.
- Convertible notes feature a conversion price of 95% of the lowest VWAP fifteen days prior to notice.
- Warrant agreement allows White Lion to purchase up to $4,000,000 in Common Stock at an exercise price of $1.584 or as otherwise defined.
- Amended ELOC allows for issuance of up to $78.9 million in Common Stock (subject to a 3,853,467 share exchange cap).
- Company must allocate 10% of proceeds from ELOC/warrant exercises toward repaying the convertible notes.
OSR Holdings, Inc. filed an 8-K/A to amend a previous filing from February 14, 2025. The amendment provides audited financial statements and pro forma condensed combined financial information for 'Legacy OSR' (OSR Holdings Co., Ltd.) covering fiscal years 2023 and 2024.
🚩 Red Flags
- The filing is an '8-K/A' (Amendment), which often indicates that the original information filed was incomplete or required correction to meet regulatory standards.
- The inclusion of 'Legacy OSR' audited financials and pro forma data suggests a complex restructuring, merger, or business combination that has not yet been fully reflected in the company's primary reporting.
📋 Key Facts
- Filing is an Amendment to a previously filed 8-K dated February 14, 2025.
- Includes audited consolidated financial statements of Legacy OSR for the years ended December 31, 2024, and 2023 (Exhibit 99.1).
- Includes Management’s Discussion and Analysis (MD&A) for Legacy OSR for fiscal years 2023 and 2022 (Exhibit 99.2).
- Provides unaudited pro forma condensed combined balance sheet as of December 31, 2024, and statements of operations for 2023 and 2024 (Exhibit 99.3).
- Auditor consent provided by RSM Shinhan Accounting Corporation.
OSR Holdings, Inc. announced the appointment of Dr. Constance Höfer as Chief Scientific Officer, effective March 24, 2025. The company aims to strengthen its scientific strategy and innovation pipeline through her extensive experience in oncology and immunology.
📋 Key Facts
- Dr. Constance Höfer appointed as Chief Scientific Officer on March 24, 2025.
- Dr. Höfer joins from Merck Healthcare with over 20 years of experience in drug development (oncology/immunology).
- Compensation includes a base salary of $300,000 per year and participation in the Company's Equity-based Compensation Plan.
- The appointment is effective immediately as of March 24, 2025.
OSR Holdings, Inc. entered into a Common Stock Purchase Agreement and Registration Rights Agreement with White Lion GBM Innovation Fund. The agreement allows the company to require White Lion to purchase up to $80 million in common stock through various notice methods (Rapid or VWAP).
🚩 Red Flags
- Death Spiral Financing characteristics: The use of VWAP-based pricing and rapid purchase notices is a hallmark of dilutive financing structures often used by distressed companies.
- Significant potential dilution: An aggregate cap of $80 million in new equity represents massive potential dilution for existing shareholders.
- Termination clause linked to bankruptcy: Explicitly mentions termination upon filing for bankruptcy, indicating the lender's protection against insolvency.
📋 Key Facts
- Entered into a Common Stock Purchase Agreement and White Lion RRA on February 25, 2025.
- The company has the right to require White Lion to purchase up to $80,000,000 in aggregate gross purchase price of newly issued common stock.
- Single sales notices are capped at $2,000,000 per notice.
- Purchase methods include 'Rapid Purchase Notice' and 'VWAP Purchase Notice'.
- The company will issue White Lion shares equal to $800,000 divided by the closing price of the stock as consideration for the commitment.
- Agreement terminates on December 31, 2026, or upon bankruptcy/insolvency events.
OSR Holdings, Inc. (formerly Bellevue Life Sciences Acquisition Corp.) completed its business combination with OSR Holdings Co., Ltd. on February 14, 2025. The transaction resulted in the company transitioning from a SPAC to an operating entity owning approximately 67% of OSR Common Stock.
🚩 Red Flags
- Significant concentration of ownership: Kuk Hyoun Hwang controls 67.8% of the common stock.
- Potential future dilution/liquidity event: Non-participating stockholders hold 22% with Put/Call rights exercisable starting January 1, 2026.
📋 Key Facts
- Closing Date: February 14, 2025
- The Company issued 16,282,047 shares of common stock to Participating Stockholders in exchange for ~67% of OSR's outstanding shares.
- Kuk Hyoun Hwang holds approximately 67.8% of the outstanding shares of the Company Common Stock as of the closing date.
- Non-Participating Stockholders hold an additional 22% and have Put/Call rights exercisable on or after January 1, 2026 (or upon a change in control).
- Lock-up agreements were entered into with Bellevue Capital Management LLC, BCM Europe AG, Sung Jae Yu, and Sung Hoon Chung.
- The company has ceased to be a shell company following the consummation of the business combination.
OSR Holdings, Inc. (formerly Bellevue Life Sciences Acquisition Corp.) announced the successful closing of its business combination with OSR Holdings Co., Ltd., a South Korean corporation. This marks the transition from a SPAC to an operating entity.
🚩 Red Flags
- The company is transitioning from a SPAC structure, which often involves significant dilution or complex capital structures involving warrants and rights.
📋 Key Facts
- The company completed its business combination on February 14, 2025.
- The registrant changed its name from Bellevue Life Sciences Acquisition Corp. to OSR Holdings, Inc.
- The transaction involves the merger with OSR Holdings Co., Ltd., organized under the laws of the Republic of Korea.
- Trading units (BLACU), common stock (BLAC), redeemable warrants (BLACW), and rights (BLACR) were previously listed on Nasdaq.
Bellevue Life Sciences Acquisition Corp. (BLAC) successfully held a special meeting on February 13, 2025, where shareholders overwhelmingly approved the business combination with OSR Holdings, Inc. The vote includes approval for name changes, charter amendments, and director elections to facilitate the merger.
🚩 Red Flags
- Redemption activity: 57,821 shares were redeemed, indicating some shareholders chose to exit rather than participate in the merger.
📋 Key Facts
- Shareholders approved the Business Combination Proposal (Proposal No. 1) with 2,175,065 votes in favor.
- The company will change its name from Bellevue Life Sciences Acquisition Corp. to OSR Holdings, Inc.
- A quorum of 93.95% of voting power was represented at the meeting.
- 57,821 shares of BLAC Common Stock were tendered for redemption in connection with the votes.
- The Amended and Restated Certificate of Incorporation was filed on February 13, 2025.
Bellevue Life Sciences Acquisition Corp. has entered into a second amendment to its existing promissory notes with its sponsor, Bellevue Global Life Sciences Investors, LLC. The amendment extends the maturity date of all outstanding notes to September 30, 2025, regardless of whether a business combination is completed before that date.
🚩 Red Flags
- Related-party transaction: The debt is owed directly to the company's Sponsor (Bellevue Global Life Sciences Investors, LLC).
- SPAC liquidity pressure: The extension of maturity dates suggests the company has not yet consummated a business combination and is managing its runway/obligations with the sponsor.
📋 Key Facts
- The Company issued four unsecured promissory notes to its Sponsor on various dates in 2024 totaling $1,690,000 in principal.
- Principal amounts: $1,200,000 (April 8), $50,000 (April 17), $140,000 (May 14), and $300,000 (July 11).
- The second amendment was entered into on January 23, 2025.
- Maturity date is now set to September 30, 2025, removing the previous contingency regarding business combination timing.
Bellevue Life Sciences Acquisition Corp. has amended existing unsecured promissory notes with its sponsor, Bellevue Global Life Sciences Investors, LLC. The amendment extends the maturity date of these obligations to either September 30, 2025, or the date of an initial business combination.
🚩 Red Flags
- Related-party transaction: The debt is owed to the company's own sponsor.
- SPAC liquidity pressure: Extension of promissory notes often indicates a delay in finding a target or completing a business combination (de-SPAC).
- Tight timeline: A maturity date of September 30, 2025, provides a limited window for the SPAC to complete its merger before facing potential default/repayment obligations.
📋 Key Facts
- The Company is amending four previously issued unsecured promissory notes totaling $1,690,000 in principal amount.
- Original note amounts: $1,200,000 (April 8, 2024), $50,000 (April 17, 2024), $140,000 (May 14, 2024), and $300,000 (July 11, 2024).
- The amendment extends the maturity date to the earlier of September 30, 2025, or the consummation of an initial business combination.
- The counterparty is the Company's Sponsor, Bellevue Global Life Sciences Investors, LLC.
Bellevue Life Sciences Acquisition Corp. (BLAC) has entered into two significant amendments related to its ongoing business combination and financing. These include an amendment to a $20 million PIPE subscription agreement with Toonon Partners Co., Ltd. and an amendment to the Business Combination Agreement with OSR Holdings Co., Ltd.
🚩 Red Flags
- Related-party transaction: The CEO (Kuk Hyoun Hwang) is also the Chairman of the target company, OSR Holdings Co., Ltd.
- Complexity in financing: Amendments to remove redemption features from preferred stock can impact the capital structure and investor rights.
📋 Key Facts
- Amended the Subscription Agreement with Toonon Partners Co., Ltd. (dated Oct 4, 2024) to remove redemption features of the Series A Preferred Stock.
- The original PIPE investment involves 222,222 shares of Series A Preferred Stock at $90.00 per share for a total of $20,000,000.
- Amended the Business Combination Agreement with OSR Holdings Co., Ltd. to include termination dates for put and call rights in the Non-Participating Stockholder Joinder.
- CEO Kuk Hyoun Hwang serves as Chairman of the Board of OSR Holdings, creating a potential related-party interest in the merger.
- A separate M&A Committee of independent directors was formed to review these transactions.
Bellevue Life Sciences Acquisition Corp. held an annual meeting where stockholders approved extending the business combination deadline from November 14, 2024, to February 14, 2025. Additionally, shareholders approved removing net tangible asset requirements to avoid 'penny stock' rules and re-elected all five directors.
🚩 Red Flags
- Significant redemption activity: 1,766,469 shares (approx. 50% of outstanding common stock) were tendered for redemption following the extension vote.
- The company is operating under a deadline to find a target or face liquidation/dissolution.
📋 Key Facts
- Stockholders approved an extension of the business combination deadline to February 14, 2025.
- The NTA Requirement Amendment Proposal was approved to expand methods used to avoid SEC 'penny stock' rules.
- All five existing directors were re-elected to the Board of Directors.
- Approximately 71.24% of outstanding common stock (2,878,990 shares) were present at the meeting.
- As a result of the votes, 1,766,469 shares of common stock were tendered for redemption.
Bellevue Life Sciences Acquisition Corp. has advanced a $300,000 loan to OSR Holdings Co., Ltd. via a promissory note to support working capital for the target company ahead of a proposed business combination.
🚩 Red Flags
- SPAC (Special Purpose Acquisition Company) structure often involves high risk regarding the completion of business combinations.
- The company is providing direct financing to its merger target, which can be seen as a way to sustain the target's operations prior to closing.
📋 Key Facts
- Loan amount: $300,000
- Interest rate: 3.96% per annum, compounded semi-annually
- Maturity date: October 25, 2025
- Purpose of funds: Working capital and other expenses for OSR Holdings Co., Ltd.
- The loan is part of a larger proposed business combination involving an S-4 registration statement.
Bellevue Life Sciences Acquisition Corp. issued an $800,000 unsecured promissory note to Duksung Co., LTD. on October 16, 2024. The note carries a 5% interest rate and features a conversion mechanism into common stock triggered by a 'Qualified PIPE Financing'.
🚩 Red Flags
- The issuance of debt to fund operations/bridge financing is common in SPACs nearing their deadline.
- Conversion price ($8.10) may be significantly different from current market pricing depending on volatility.
📋 Key Facts
- Principal amount of the promissory note: $800,000.
- Interest rate: 5% per annum (increases to 7% for prepayment purposes).
- Maturity Date: October 15, 2025.
- Conversion Price: Shares issued at a conversion price of $8.10 per share upon a Qualified PIPE Financing.
- Prepayment Clause: The company can prepay the note after March 31, 2025, if no PIPE financing occurs.
Bellevue Life Sciences Acquisition Corp. issued a $40,000 unsecured promissory note to a Board member, Jun Chul Whang. The note is non-interest bearing and includes a forgiveness clause if the company fails to consummate a business combination.
🚩 Red Flags
- Related-party transaction involving a Board member (Jun Chul Whang).
- The company is an SPAC in a race against time; failure to consummate a deal triggers debt forgiveness or maturity.
- Small cash amounts ($40k-$50k) relative to typical SPAC operations suggest significant liquidity constraints.
📋 Key Facts
- Issued an unsecured promissory note for $40,000 on October 10, 2024.
- The note is issued to Jun Chul Whang, a member of the Company's Board (Related Party).
- The note is non-interest bearing and payable by November 9, 2024, or upon raising capital/business combination.
- $50,000 was deposited into the trust account on October 11, 2024, to extend the business combination deadline.
Bellevue Life Sciences Acquisition Corp. entered into a $20 million PIPE investment agreement with Toonon Partners Co., Ltd. to fund its upcoming business combination with OSR Holdings Co., Ltd. The offering involves the issuance of Series A Preferred Stock with specific redemption and conversion features.
🚩 Red Flags
- Potential dilution: Conversion of Series A Preferred Stock into common stock at $9.00 per share may significantly dilute existing shareholders.
- Redemption obligations: The company faces mandatory redemption rights by the investor after three years, creating a potential future cash drain.
📋 Key Facts
- Total PIPE Investment amount: $20,000,000
- Number of shares to be issued: 222,222 shares of Series A Preferred Stock
- Price per share: $90.00 (Series A Original Issue Price)
- Conversion price for preferred stock into common stock: Initially $9.00
- Dividend rate on Series A Preferred Stock: 5% per annum (accruing); 7% per annum (for redemption purposes)
- Redemption rights: Company can redeem at the one-year anniversary; Holder can demand redemption starting at the three-year anniversary.
- Registration rights: The company is obligated to file a registration statement for the PIPE shares upon written demand from Toonon.
Bellevue Life Sciences Acquisition Corp. has received a decision from the Nasdaq Hearings Panel granting a continued listing exception. The company must demonstrate compliance with the Minimum Public Holders Requirement (Nasdaq Listing Rule 5505) by February 17, 2025.
🚩 Red Flags
- Delisting/Non-compliance notice: The company has already failed one compliance period regarding the Minimum Public Holders Requirement.
- Regulatory risk: Continued listing is contingent upon meeting specific shareholder distribution requirements by February 2025.
📋 Key Facts
- The company failed to meet the minimum 300 public holders requirement during the initial compliance period ending August 13, 2024.
- A hearing was held on October 1, 2024, following a request by the company to stay delisting actions.
- The Nasdaq Hearings Panel granted continued listing subject to demonstrating compliance with Rule 5505 by February 17, 2025.
- The company is required to provide prompt notification of any significant events that may affect its compliance during this exception period.
Bellevue Life Sciences Acquisition Corp. has amended two existing unsecured promissory notes to extend their maturity dates for a Board member and the Company's Sponsor.
🚩 Red Flags
- Related-party transactions: Both notes are owed to insiders (a Director and a member of the Sponsor).
- Extension of debt maturity suggests the company is delaying repayment obligations, likely due to lack of liquidity or pending business combination.
📋 Key Facts
- Amended the $75,000 Whang Promissory Note (issued to Director Jun Chul Whang) to extend maturity to March 31, 2025, or upon business combination.
- Amended the $60,000 Pan Promissory Note (issued to Josh Pan, member of the Company's Sponsor) to extend maturity to March 31, 2025, or upon business combination.
- The amendments were executed on September 20, 2024.
Bellevue Life Sciences Acquisition Corp. reported a $50,000 deposit into its trust account to facilitate an extension of the deadline for completing a business combination.
🚩 Red Flags
- SPAC extension activity often indicates difficulty finding a target or completing a merger within the original timeframe.
📋 Key Facts
- Date of event: September 10, 2024
- Amount deposited in trust: $50,000
- Purpose of deposit: Extension of the date by which the Company must consummate a business combination
- The company is an emerging growth company
Bellevue Life Sciences Acquisition Corp. has failed to regain compliance with Nasdaq's minimum 300 public holders requirement despite an extension. The company intends to request a hearing before a Nasdaq Hearings Panel to stay potential delisting or suspension.
🚩 Red Flags
- Failure to meet minimum public holder requirements (Nasdaq Rule 5550(a)(3))
- Imminent risk of securities suspension or delisting from Nasdaq
- SPAC/Acquisition Corp structure often faces liquidity and shareholder count challenges during the de-SPAC process.
📋 Key Facts
- The Company received a 'Second Notice' from Nasdaq on August 20, 2024, confirming failure to meet the Minimum Public Holders Requirement.
- Nasdaq Rule 5550(a)(3) requires a minimum of 300 public holders for the Nasdaq Capital Market.
- The compliance period granted by Nasdaq expired on August 13, 2024.
- The Company intends to timely request a hearing before a Hearings Panel to stay any suspension or delisting action.
Bellevue Life Sciences Acquisition Corp. reported a $50,000 deposit into its trust account to facilitate an extension of the deadline for completing a business combination.
🚩 Red Flags
- SPAC extension: The need to extend the deadline for a business combination indicates the company has not yet found a target or closed a deal within its original timeframe.
📋 Key Facts
- On August 13, 2024, $50,000 was deposited into the company's trust account.
- The deposit is specifically related to extending the date by which the Company must consummate a business combination.
- The company is an emerging growth company.
Bellevue Life Sciences Acquisition Corp. issued a $300,000 unsecured promissory note to its sponsor, Bellevue Global Life Sciences Investors, LLC. The note is non-interest bearing and matures on December 31, 2024, or upon completion of a business combination.
🚩 Red Flags
- Related-party transaction: The debt is owed directly to the company's sponsor (BGLSI).
📋 Key Facts
- Issued an unsecured promissory note for $300,000 to the company's sponsor (BGLSI) on July 11, 2024.
- The note is non-interest bearing.
- Maturity date is either December 31, 2024, or the date of a business combination.
- Sponsor has agreed to forgive the principal if no business combination occurs by the deadline (subject to trust account funds).
- $50,000 was deposited into the trust account on July 12, 2024, related to an extension for consummating a business combination.
Bellevue Life Sciences Acquisition Corp. announced the appointment of Sang Hyun Kim to its Board of Directors, effective June 23, 2024. Mr. Kim will serve on the Audit Committee, Compensation Committee, and M&A Committee, filling vacancies left by previous resignations.
🚩 Red Flags
- Multiple vacancies in key committees (Audit, Compensation, M&A) being filled simultaneously suggests recent turnover/instability in governance structure.
📋 Key Facts
- Sang Hyun Kim appointed as a director effective June 23, 2024.
- Appointed to the Audit Committee (replacing Inchul Chung).
- Appointed to the Compensation Committee and M&A Committee (replacing Radclyffe Roberts).
- Mr. Kim is an independent director per Nasdaq standards.
- No compensation will be provided for his services as a director.
- Mr. Kim has extensive experience at Samsung Group and Korea Daesung Asset Management Co., Ltd.
Bellevue Life Sciences Acquisition Corp. reported the immediate resignation of two board members, resulting in non-compliance with Nasdaq's independence and committee composition requirements. The company has notified Nasdaq and intends to seek a cure period to regain compliance.
🚩 Red Flags
- Delisting risk due to failure to satisfy Nasdaq's majority independent board and committee composition requirements.
- Multiple officer/director departures in a single filing (Inchul Chung and Radclyffe Roberts).
- Non-compliance with specific Nasdaq Listing Rules 5605(b)(1), 5605(d)(2)(A) and 5605(c)(2)(A.
📋 Key Facts
- Inchul Chung resigned from the Board and Audit Committee on June 7, 2024; resignation was not due to any disagreement with the Company.
- Radclyffe Roberts resigned from the Board, Compensation Committee, and M&A Committee on June 7, 2024; resignation was not due to any disagreement with the Company.
- The company is currently non-compliant with Nasdaq Listing Rules 5605(b)(1), 5605(d)(2)(A), and 5605(c)(2)(A regarding board independence and committee composition.
- Nasdaq was notified of the non-compliance on June 13, 2024.
- The company intends to regain compliance within the provided cure period.
- A $50,000 contribution was deposited into the trust account on June 13, 2024.
Bellevue Life Sciences Acquisition Corp. (BLAC) has entered into an Amended and Restated Business Combination Agreement with OSR Holdings Co., Ltd. to update the terms of their proposed merger, including a reduction in total aggregate consideration.
🚩 Red Flags
- Reduction in total aggregate consideration and share count for the merger target.
- Potential conflict of interest: CEO Kuk Hyoun Hwang serves as both CEO/Board member of BLAC and CEO/Chairman of the target company, OSR Holdings Co., Ltd.
📋 Key Facts
- Amended and Restated Business Combination Agreement signed on May 23, 2024.
- Aggregate Consideration reduced from 25,033,961 shares to 24,461,214 shares of BLAC Common Stock.
- Aggregate Consideration Value reduced from $250,339,610 to $244,612,136.
- Removal of references to the proposed acquisition by the Company of Landmark BioVentures AG.
- Changes made to the designation of the post-closing Board of Directors.
Bellevue Life Sciences Acquisition Corp. (a SPAC) successfully held a special meeting to extend its deadline for completing a business combination from May 14, 2024, to November 14, 2024. The filing also notes the issuance of a $140,000 unsecured promissory note to the company's sponsor and significant shareholder redemptions.
🚩 Red Flags
- Significant shareholder redemptions (1.58M+ shares) reduce the cash available in the trust account.
- The company is operating under an extension, indicating it has not yet found a target or completed a merger by its original deadline.
- Reliance on sponsor contributions ($50k increments) to maintain the trust account during the extension period.
📋 Key Facts
- Stockholders approved an extension to consummate a business combination by November 14, 2024.
- The Company issued a non-interest bearing $140,000 unsecured promissory note to its sponsor, Bellevue Global Life Sciences Investors LLC (BGLSI).
- The promissory note is payable on December 31, 2024, or upon consummation of a business combination.
- Sponsor agreed to deposit $50,000 into the trust account by specific monthly dates through October 2024 to support the extension.
- Approximately 1,581,733 shares of common stock were tendered for redemption in connection with the vote.
Bellevue Life Sciences Acquisition Corp. (a SPAC) filed an 8-K to furnish a press release pursuant to Regulation FD. The filing primarily serves as a vehicle to disseminate information regarding the company's units, warrants, and rights.
📋 Key Facts
- The filing is made under Item 7.01 (Regulation FD Disclosure).
- The company issued a press release on May 13, 2024, which is incorporated by reference as Exhibit 99.1.
- Securities mentioned include Units (BLACU), Common Stock (BLAC), Redeemable Warrants (BLACW) with an exercise price of $11.50 per share, and Rights (BLACR).
- The company is classified as an emerging growth company.
Bellevue Life Sciences Acquisition Corp. adjourned its Special Meeting of Stockholders scheduled for May 10, 2024, without conducting any business. The meeting is now reconvened for Tuesday, May 14, 2024.
🚩 Red Flags
- Adjournment of a Special Meeting often indicates failure to reach a quorum or insufficient proxy support for a proposed business combination/extension.
- SPACs facing meeting adjournments are typically in the final stages of their lifecycle and may be struggling to secure necessary shareholder votes.
📋 Key Facts
- Special Meeting originally held on May 10, 2024, was adjourned without action.
- The Special Meeting has been rescheduled for May 14, 2024, at 9:00 a.m. Pacific time.
- Stockholders who previously tendered shares for redemption may withdraw their tender prior to the new meeting date by contacting Continental Stock Transfer & Trust Company.
- Proxy solicitation is ongoing to secure votes for matters described in the April 26, 2024 Proxy Statement.
Bellevue Life Sciences Acquisition Corp. (a SPAC) has received an extension from Nasdaq to regain compliance with the minimum 300 public holders requirement. Additionally, the company issued a $50,000 unsecured promissory note to its sponsor.
🚩 Red Flags
- Delisting risk: Failure to meet the 300 public holder requirement by August 13, 2024, will result in delisting.
- SPAC lifecycle pressure: The promissory note maturity date (Dec 31, 2024) creates a tight timeline for completing a business combination.
📋 Key Facts
- Received notice from Nasdaq on Feb 15, 2024, regarding failure to meet the Minimum Public Holders Requirement (Nasdaq Listing Rule 5550(a)(3)).
- Nasdaq granted an extension to regain compliance until August 13, 2024.
- Compliance requires demonstrating a minimum of 300 public holders via transfer agent documentation by the deadline.
- Issued a $50,000 unsecured, non-interest bearing promissory note to sponsor Bellevue Global Life Sciences Investors LLC on April 17, 2024.
- The promissory note matures on Dec 31, 2024, or upon consummation of a business combination, whichever is earlier.
Bellevue Life Sciences Acquisition Corp. issued a $1.2 million unsecured, non-interest-bearing promissory note to its sponsor, Bellevue Global Life Sciences Investors, LLC. The filing also notes an extension of the business combination deadline to May 14, 2024.
🚩 Red Flags
- Related-party transaction: The $1.2M debt is owed directly to the company's sponsor.
- Tight timeline: The business combination deadline has been extended to May 14, 2024, indicating a high-pressure window for completing a merger.
📋 Key Facts
- Issued an unsecured promissory note for $1,200,000 on April 8, 2024.
- The note is issued to Bellevue Global Life Sciences Investors, LLC (the Sponsor).
- The note is non-interest bearing and matures on December 31, 2024, or upon consummation of a business combination, whichever is earlier.
- Sponsor has agreed to forgive the principal balance if no business combination occurs by the deadline, subject to funds remaining in the trust account.
- The company deposited $60,000 into its trust account on April 9, 2024, to extend the business combination deadline from April 15, 2024, to May 14, 2024.
Bellevue Life Sciences Acquisition Corp. issued a $60,000 unsecured promissory note to Josh Pan, an individual member of the company's sponsor. The note is non-interest bearing and matures on August 8, 2024, or upon business combination.
🚩 Red Flags
- Related-party transaction: The debt is owed to an individual member of the company's sponsor.
- SPAC deadline pressure: The company has extended its business combination deadline to April 15, 2024, indicating a time-sensitive search for a target.
📋 Key Facts
- Issued an unsecured promissory note for $60,000 principal amount on March 8, 2024.
- The note is issued to Josh Pan, a member of Bellevue Capital Management, LLC (the sponsor).
- The note is non-interest bearing.
- Maturity date is August 8, 2024, or the date of business combination, whichever is earlier.
- Mr. Pan has agreed to forgive the principal if no business combination occurs by the deadline in the Certificate of Incorporation (subject to extension).
- A $60,000 deposit was made into the trust account on March 12, 2024, related to a business combination deadline extension from March 14, 2024, to April 15, 2024.
Bellevue Life Sciences Acquisition Corp. received a notice from Nasdaq stating it no longer meets the minimum 300 public holders requirement for the Nasdaq Capital Market. The company has until April 1, 2024, to submit a compliance plan.
🚩 Red Flags
- Delisting notice regarding minimum public holder requirements
- Potential for loss of exchange listing if compliance plan is rejected or not implemented
📋 Key Facts
- Notice received on February 15, 2024, from Nasdaq Listing Qualifications Department.
- Failure to meet Nasdaq Listing Rule 5550(a)(3) regarding the Minimum Public Holders Requirement (300 public holders).
- The company has 45 calendar days (until April 1, 2024) to submit a plan to regain compliance.
- If a plan is accepted, Nasdaq may grant an extension of up to 180 calendar days.
Bellevue Life Sciences Acquisition Corp. issued a $75,000 unsecured promissory note to a Board member and filed an amendment to extend its business combination deadline.
🚩 Red Flags
- Related-party transaction: The company is personally indebted to a member of its own Board of Directors.
- SPAC deadline pressure: Multiple extensions indicate the company is struggling to find a target or complete a merger within original timelines.
📋 Key Facts
- Issued an unsecured, non-interest bearing promissory note of $75,000 to Director Jun Chul Whang on February 9, 2024.
- The note is payable by August 9, 2024, or upon consummation of a business combination.
- Director agrees to forgive the note if no business combination occurs by the extended deadline (subject to trust account funds).
- Charter Amendment filed on February 9, 2024, extends the business combination deadline from February 14, 2024, to May 14, 2024.
- $60,000 was deposited into the trust account in connection with a previous extension.